RecruitingNot applicableNCT06964815

Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients

Studying Glioblastoma

Last synced from ClinicalTrials.gov May 4, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Istituto Oncologico Veneto IRCCS
Intervention: Silibinin as STAT3 inhibitor(dietary_supplement)
Enrollment: 110 enrolled
Eligibility: 18-99 years · All sexes
Timeline: 2025 – 2027

Study locations (16)

IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, BO, Italy
IRST Dino Amadori, Meldola, FC, Italy
Azienda Ospedaliero Universitaria Policlinico "G. Rodolico - San Marco ", Catania, Italia/Catania, Italy
Azienda Ospedaliera Universitaria - Careggi, Florence, Italia/FI, Italy
ARNAS G.Brotzu P.O Armando Businco, Cagliari, Italy/Cagliari, Italy
USL Nord Ovest Toscana - Livorno, Livorno, Italy/Livorno, Italy
Ospedale del Mare, ASL Napoli1 Centro, Naples, italy/Napoli, Italy
Istituto Oncologico Veneto, Padua, Italy/Padova, Italy
Istituto Neurologico Nazionale a Carattere Scientifico IRCCS - Fondazione Mondino, Pavia, Italy/Pavia, Italy
Azienda Ospedaliera Universitaria G.Martino, Messina, ME, Italy
Istituto Tumori Regina Elena IRCCS, Roma, RM, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, RM, Italy
Policlinico San Martino - Genova, Genova, Italy
Ospedale A. Manzoni Lecco, Lecco, Italy
Humanitas Cancer Center, Milan, Italy
+1 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06964815 on ClinicalTrials.gov

Other trials for Glioblastoma

Additional recruiting or active studies for the same condition.

See all trials for Glioblastoma →

← Back to all trials